Let’s Look at a Biotech Company with a Strong Pipeline, Upcoming Catalysts and a Market Value that Looks Way Oversold

Good Morning, New NASDAQ Report Coming Wednesday, July 6, 2022, at or Near the Market Open

The current equities market favors the bold.

Good day everyone,

H122 is now history. For many investors it was the worst decline in the stock market and cryptocurrencies they’ve ever seen.

There are a lot of NASDAQ stocks that look like a great value right now, trading less than book value, or way off their recent highs. Bold investors are buying now, knowing that equity values will go up at some unknown point, they always do.

We continue to identify opportunities in this market. Even in this market we’ve issued some reports that have offered significant potential near-term benefit for our group. We continue to scour the small cap equities market to identify more.

I want to revisit a NASDAQ biopharma company that is beginning to gain back some of the value lost in the NASDAQ rout. Our new report will cover a NASDAQ company with a product already in the market, others in clinical trials and collaborative ventures with other companies.

I believe that when you evaluate this company’s pipeline and then look at their market value you will agree with me that the company is oversold. When you see the chart setup you might see a swing building near term, just as I did. The company has a very tiny float, plenty of cash on hand, and a unique potential incentive for stakeholders.

Stay tuned and stay informed. We will issue this report on Wednesday, July 6, 2022, at or near the market open.

The Traders News Team